Inflammatory bowel disease in liver transplanted patients
- PMID: 28566881
- PMCID: PMC5434427
- DOI: 10.3748/wjg.v23.i18.3214
Inflammatory bowel disease in liver transplanted patients
Abstract
Most common hepatobiliary manifestation of inflammatory bowel disease (IBD) are primary sclerosing cholangitis (PSC) and autoimmune hepatitis, ranking them as the main cause of liver transplantation (LT) in IBD setting. Course of pre-existing IBD after LT differs depending on many transplant related factors. Potential risk factors related to IBD deterioration after LT are tacrolimus-based immunosuppressive regimens, active IBD and cessation of 5-aminosalicylates at the time of LT. About 30% patients experience improvement of IBD after LT, while approximately the same percentage of patients worsens. Occurrence of de novo IBD may develop in 14%-30% of patients with PSC. Recommended IBD therapy after LT is equivalent to recommendations to overall IBD patients. Anti-tumor necrosis factor alpha appears to be efficient for refractory IBD. Due to potential side effects it needs to be applied with caution. In average 9% of patients require proctocolectomy due to medically refractory IBD or colorectal carcinoma. The most frequent complication in patients who undergo proctocolectomy with ileal-pouch anal anastomosis is pouchitis. It is still undeterminable if LT adds to risk of developing pouchitis in PSC patients. Annual colonoscopies are recommended as surveillance and precaution of colonic malignancies.
Keywords: Anti-TNF alpha therapy; Immunomodulatory therapy; Immunosuppression; Inflammatory bowel disease; Liver transplantation; Proctoproctocolectomy; Risk factors.
Conflict of interest statement
Conflict-of-interest statement: All authors who have taken part in this study declared that they have nothing to disclose regarding funding or conflict of interest with respect to this manuscript.
Similar articles
-
Clinical management of inflammatory bowel disease in the organ recipient.World J Gastroenterol. 2014 Apr 7;20(13):3525-33. doi: 10.3748/wjg.v20.i13.3525. World J Gastroenterol. 2014. PMID: 24707135 Free PMC article. Review.
-
Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series.Dig Liver Dis. 2018 Jul;50(7):668-674. doi: 10.1016/j.dld.2018.02.014. Epub 2018 Mar 13. Dig Liver Dis. 2018. PMID: 29655972
-
Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.Am J Gastroenterol. 2013 Sep;108(9):1417-25. doi: 10.1038/ajg.2013.163. Epub 2013 Jul 30. Am J Gastroenterol. 2013. PMID: 23896954 Review.
-
Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.Inflamm Bowel Dis. 2018 Jan 18;24(2):269-276. doi: 10.1093/ibd/izx056. Inflamm Bowel Dis. 2018. PMID: 29361103 Review.
-
Ileal Pouch-anal Anastomosis in Primary Sclerosing Cholangitis-inflammatory Bowel Disease (PSC-IBD): Long-term Pouch and Liver Transplant Outcomes.Ann Surg. 2023 Dec 1;278(6):961-968. doi: 10.1097/SLA.0000000000006041. Epub 2023 Jul 21. Ann Surg. 2023. PMID: 37477000
Cited by
-
Diagnosis and management of de novo inflammatory bowel disease after solid organ transplantation in the era of biologic therapy: a case series.Front Transplant. 2025 Jan 8;3:1483943. doi: 10.3389/frtra.2024.1483943. eCollection 2024. Front Transplant. 2025. PMID: 39846032 Free PMC article.
-
Impact of liver transplantation on intestinal and systemic inflammation markers in patients with colitis ulcerosa concomitant with primary sclerosing cholangitis.Prz Gastroenterol. 2024;16(4):439-445. doi: 10.5114/pg.2024.145575. Epub 2024 Dec 4. Prz Gastroenterol. 2024. PMID: 39810863 Free PMC article.
-
Comparison of time-to-event machine learning models in predicting biliary complication and mortality rate in liver transplant patients.Sci Rep. 2025 Feb 8;15(1):4768. doi: 10.1038/s41598-025-89570-4. Sci Rep. 2025. PMID: 39922959 Free PMC article.
-
Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver.Int J Mol Sci. 2018 Jul 27;19(8):2199. doi: 10.3390/ijms19082199. Int J Mol Sci. 2018. PMID: 30060508 Free PMC article. Review.
-
Concurrent inflammatory bowel disease and primary sclerosing cholangitis: a review of pre- and post-transplant outcomes and treatment options.Gastroenterol Hepatol Bed Bench. 2023;16(3):259-269. doi: 10.22037/ghfbb.v16i2.2589. Gastroenterol Hepatol Bed Bench. 2023. PMID: 37767322 Free PMC article. Review.
References
-
- Podolsky DK. Inflammatory bowel disease. N Eng J Med. 2002;347:417–429. - PubMed
-
- Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis. 1991;11:31–39. - PubMed
-
- Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–678. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical